Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of encorafenib + cetuximab with or without binimetinib versus irinotecan/cetuximab or FOLFIRI/cetuximab in BRAF V600E-mutant metastatic colorectal cancer
2015-005805-35Phase 3Unknown
- Sponsor
- Array BioPharma
- Start
- Aug 2016
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of encorafenib, cetuximab, binimetinib, irinotecan, fluorouracil and 1 more in colorectal cancer (CRC) and metastatic colorectal adenocarcinoma (mCRC) (4 arms), sponsored by Array BioPharma. Primary endpoint: Safety and tolerability. Status: unknown.
02
Drugs
encorafenibcetuximabbinimetinibirinotecanfluorouracil
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2015-005805-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005805-35.